About

_

asa

Today, a single pharmaceutical drug often crosses three continents during its lengthy production process before reaching the patient. What if we could shorten this process, simplifying the supply chain, increasing efficiency and reducing waste?

The CassaFLOW innovative consortium has started to address this challenge. We are composed of experts from European research organisations and promising SMEs, supported by the European Innovation Council. The experts from Delft University of Technology (Prof. Ulf Hanefeld), Eindhoven University of Technology (Prof. Jan van Hest) and Bielefeld University (Prof. Harald Gröger) have successfully worked together to develop the innovative reaction telescoping and flow chemistry ONEFLOW technology, a key element which cassaFLOW will build upon. Two experienced industrial partners, Chiralvision (Managing Director Rob Schoevaart) and SpinChem (CEO Emil Byström) will contribute with their expertise in enzyme immobilization, sustainable carrier materials and fine chemicals (Chiralvision) and engineering for intensification of biocatalytic processes (SpinChem).

Our consortium is further advised by experts from several industries, such as Bachem, Evonik, BASF, Symeres, Jiuzhou Pharmaceutical and GSK, ensuring a strong basis in market development in the peptide, biocatalysis and pharmaceutical fields.

Building on the Technology of ONE-FLOW

Our previous FET-OPEN project serves as the technological basis for cassaFLOW

In this project, a sequential-type and a tandem-type chemoenzymatic flow cascade was developed, where products were accessible via a sequential flow approach. As no purification is needed between the two reaction steps, it can be seen as a two-step “one-flow” process. (Eur. J. Org. Chem., 2022, 7, e202101035)